source
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cureGSK and Ionis announced that the U.S. Food and Drug Administration has approved their hepatitis B drug bepirovirsen, now marketed as Hibsago. The therapy is intended for chronic hepatitis B patien…
- German biotech Immatics eyes pivotal Phase 3 readout after promising uveal melanoma cell therapy resultsImmatics, a German biotech founded 26 years ago, is focusing on cancer immunotherapy. Its lead candidate is an experimental cell therapy targeting uveal melanoma. Early Phase 1 data in 16 patients…